New approaches in alternative energy sources and food production, fermentation processes, modified enzymes for processing technologies – PROvendis offers various biotechnologies for licensing, to purchase or for development cooperation.

Don't hesitate to contact us! You can also find further contact persons in each technology offer.


Photocage Cap for mRNAs

Almost all eukaryotic messenger RNAs (mRNAs) are modified at their 5'-ends by a cap that is synthesised by addition of a 7-methylguanosine attached via a 5'-5' triphosphate bridge to the first transcribed nucleotide of the mRNA chain.

Artificial Interferons

The invention comprises IFNα2 mutants achieved by designing an IFNα2 with amino acids from IFNα14, which significantly improved their antiviral activity against chronic HBV. As IFNα14 is not suitable for use as a drug, unlike IFNα2, and considering that the IFNα2 mutant is almost as effective as IFNα14, it appears the IFNα2 mutant could be a viable option for clinical application.

Cyclic AMP Biosensor

Cyclic AMP is a key molecule in 2nd messenger cell signalling. Great effort has been taken to develop sensors that allow for noninvasive assessment of cAMP concentrations in living cells.

Enantiomerically pure chiral N-acyl-a-aminonitriles

Enantiomerically pure N-acyl-a-aminonitriles gained these days interest in the pharmaceutical industry since a range of recently developed pharmaceuticals are based on this product class.

Improving aspirin solubility

Acetylsalicylic acid (ASA) is one of the most prescribed non-steroidal anti-inflammatory drugs. However, the substance suffers from poor water solubility. The invention provides a reproducible method to produce ASA-nicotinic acid amide co-crystals with improved solubilty and bioavailability.

Supplements for T Cell-Based Immunotherapy

Optimized conceot for the activation of CAR T cells and prevention of exhaustion in the treatment of cancer.

Synthetic Cytokine Receptors

Synthetic cytokine receptors (SyCyRs) enable defined background-free cellular responses through addition of synthetic ligands. The system allows the engineering of highly specific amplification or eradication switches for recombinant cells.

Submerged Bioprinting

The present invention allows to print the conduits submerged in non-miscible solvents of high density, such as fluorocarbons (e.g. C12F27N), that support the printed structure while it is being generated resulting in superior performance in relation to other methods. Viable cells 24 h after the printing process, as well as after 21 days in culture.

3D-TAM (Tumour Angiogenesis Model)

This model can be used to analyse tumour groth, tumour angiogenesis and therapeutic effects on the 3D-printed cell model. No animal tissue is needed. Therefore, this 3D-printed Tumour Model represents an ideal in-vitro-prescreening system for testing pharmaceuticals and diagnostics and might be able to circumvent or at least reduce the number of animal tests in drug development.

New Cryptophycins for ADC and SMDC

The present invention combines new synthetic ways to new Cryptophycin derivatives with alternative conjugation possibilites and pico-molar cytotoxicies, for ADC and SMDC synthesis.

High-Redshift BODIPY Dyes

Fluorescent molecules are widely used in bioimaging and medicinal applications for several decades due to their high sensitivity and easy visibility.

Plasma Biocatalysis

Enzymatic reactions offer the possibility to synthesize new molecules with high selectivity and turnover.